## Table 21.8 Cancer of the Ovary(Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<65	65+	All	<65	65+	All	<65	65+
-Year Relative Survival	(Percent)								
Year of Diagnosis:	(10100110)								
1960-1963 <sup>a</sup>	_	_	_	32	_	_	32	-	-
1970-1973 <sup>a</sup>	-	_	_	36	_	_	32	-	_
1975–1977 <sup>b</sup>	36.0	44.2	21.4	35.3	43.5	21.1	41.8	48.9	24.9 <sup>9</sup>
1975-1977 1978-1980 <sup>b</sup>	37.7	44.2	21.4	36.8	45.5	22.4	41.0 38.8	40.9	12.8
1978-1980 1981-1983 <sup>b</sup>	38.8	50.2	22.2	38.5	50.2	22.4 23.1	30.0	49.2	22.6
1984-1986 <sup>b</sup>	38.4	49.4	24.0	37.5	48.5	23.7	39.3	52.1	21.2
1987-1989 <sup>b</sup>	38.1	51.0	23.6	38.1	51.2	23.9	33.6	46.9	16.9
1990-1992 <sup>b</sup>	40.4	55.3	24.1	40.3	55.9	24.1	35.8	49.7	16.8
1993-1995 <sup>b</sup>	41.4	55.7	26.4	40.5	55.4	25.8	41.5	54.8	26.9
1996-1998 <sup>b</sup>	43.8	57.0	28.3	43.1	56.5	28.3	39.1	53.1	20.6
1999-2002 <sup>b</sup>	43.5	56.2	27.9	43.0	56.5	27.8	36.2	45.0	22.4
2003-2009 <sup>b</sup>	44.1 <sup>f</sup>	56.6 <sup>f</sup>	27.5 <sup>f</sup>	43.9 <sup>f</sup>	56.7 <sup>f</sup>	28.2 <sup>f</sup>	35.9	45.0	20.5
-Year Period Survival ()	Percent) <sup>cd</sup>								
2009	44.5	57.0	27.7	44.2	57.3	27.9	35.7	44.4	22.9
Stage Distribution (%) 2	JU3-2009								
All Stages									
Number of cases	33,789	18,876	14,913	28,227	15,287	12,940	2,781	1,633	1,148
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	15	20	7	14	20	7	15	20	8
Regional	18	22	13	18	22	13	15	16	12
Distant	61	55	69	62	55	69	62	58	68
Unstaged	6	3	10	6	3	10	8	6	12
-Year Relative Survival	(Percent), 2	003-2009 <sup>c</sup>							
Aqe at Diagnosis:									
Ages <45	74.8	_	_	74.9	_	_	70.2	_	_
Ages 45-54	57.5	_	-	58.5	_	_	40.0	-	-
Ages 55-64	46.2	_	_	46.8	_	_	32.2	-	_
Ages 65-74	36.9	_	_	37.8		_	24.0		_
Ages 75+	19.8	_	_	20.1	_	_	15.5	_	_
5	57.0	_	_	57.1	_	_	46.7	_	_
Ages <65						_			_
Ages 65+	27.5	-	-	28.0	-	-	20.2	-	-
Stage <sup>e</sup> :									
All Stages	44.2	57.0	27.5	44.0	57.1	28.0	36.1	46.7	20.2
Localized	91.9	93.2	87.1	91.9	93.5	86.7	88.4	90.0	80.7º
Regional	72.0	79.6	55.9	72.6	80.2	57.2	54.4	63.6	35.4
Distant	27.3	35.6	18.6	27.6	36.2	19.1	20.0	26.3	11.9
Unstaged	21.5	49.1	9.5	20.6	48.3	9.9	25.7	47.9 <sup>g</sup>	10.4

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2010.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2010.

Period survival provides a 2009 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2007-2009: 0-1 year survival), (2006-2008: 1-2 year survival), (2008-2008: 1-2 year surviv

(2006-2008: 1-2 year survival), (2005-2007: 2-3 year survival), (2004-2006: 3-4 year survival), (2003-2005: 4-5 years survival). Stage at diagnosis is classified using SEER Summary Stage 2000.

The difference between 1975-1977 and 2003-2009 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

- The standard error is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 25 cases during the time period.

b

С

d

e

f

g

h

\_